Dr. Robot gets a thumbs down from patients, according to new research from Syneos Health. Despite tech and investor enthusiasm, along with media headlines highlighting artificial intelligence in healthcare, patients are adamant that artificial intelligence should not replace doctors.
Sixty percent say “no thanks” to AI doctors, and only 16% of those surveyed saw value in “receiving a prescription or treatment recommendation from an AI assistant.”
However, the sentiment swings more positive when AI shifts to a supporting role. Patients were much more receptive when asked about ways AI can help doctors and nurses do their jobs, Syneos found.
“Sixty-four percent of people would be comfortable being supported between visits by a virtual nurse assistant providing support and monitoring for a specific prescription product,” said Duncan Arbour, senior VP of digital strategy & innovation for healthcare at Syneos, formerly inVentiv Health. “The key benefit is that people want that 24/7 access to answers.
“The No. 2 benefit that people perceive in being assisted by a virtual nursing assistant is freeing up real human medical staff to spend more time with those who need it the most,” Arbour added.
That’s a relief for healthcare providers who may be concerned about AI hype from the tech and investor sector—namely, that doctors could be replaced by machines. But what about pharma? How do drugmakers fit into an AI-assisted patient scenario?
The bad news: Patients still don’t trust pharma companies, and that extends to artificial intelligence innovations drugmakers might create. The good news, though, is that pharma clients, such as physicians and other healthcare professionals, do trust pharma.
“The opportunity lies within the trusted relationship that pharma does have with KOLs and physicians. Pharma companies are the recognized experts in their own products, even with patients,” Arbour said.
“The opportunity is to look for new partnerships to raise education and support physician audiences in developing the best virtual nurse assistants,” he said. “It has to be less about putting your brand on it and more about making sure that any AI treatment or recommendation is correct.”
Syneos surveyed 800 European and American patients with atrial fibrillation, Type 2 diabetes or breast cancer, along with 200 caregivers for people with Parkinson’s disease for the research.
By Beth Snyder Bulik
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
